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NEW HAPLOTYPES OF THE PLASMODIUM FALCIPARUM CHLOROQUINE
RESISTANCE TRANSPORTER (PFCRT) GENE AMONG CHLOROQUINE-RESISTANT
PARASITE ISOLATES
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JOHN C. REEDER, JASON D. MAGUIRE, AND J. KEVIN BAIRD
The Walter and Eliza Hall Institute for Medical Research, Melbourne, Australia; Eijkman Institute for Molecular Biology, Jakarta,
Indonesia; United States Naval Medical Research Unit No. 2, U.S. Embassy, Jakarta, Indonesia; Papua New Guinea Institute of
Medical Research, Goroka, Papua New Guinea; Australian Army Malaria Institute, Brisbane, Australia
Abstract. Mutations in the Plasmodium falciparum chloroquine resistance transporter (pfcrt) gene were examined to
assess their associations with chloroquine resistance in clinical samples from Armopa (Papua) and Papua New Guinea.
In Papua, two of the five pfcrt haplotypes found were new: SVIET from Armopa and CVIKT from an isolate in Timika.
There was also a strong association (P < 0.0001) between the pfcrt 76T allele and chloroquine resistance in 50 samples.
In Papua New Guinea, mutations in the pfcrt gene were observed in 15 isolates with chloroquine minimum inhibitory
concentrations (MICs) of 16−64 pmol, while the remaining six isolates, which had a wild-type pfcrt gene at codon 76, had
MICs of 2−8 pmol. These observations confirm that mutations at codon 76 in the pfcrt gene are present in both in vivo
and in vitro cases of chloroquine resistance, and that detection of the pfcrt 76T allele could predict potential chloroquine
treatment failures.
INTRODUCTION
Chloroquine has been the drug of choice for treating ma-
laria patients for the last 50 years, but the spread of drug-
resistant Plasmodium falciparum has become a major prob-
lem. In Southeast Asia, 21.9 million cases of malaria were
reported in 1995 alone.1,2 Malaria is a serious problem in the
eastern islands of Indonesia and in nearby Papua New
Guinea. Approximately 20−30% of the population in these
regions typically carry malaria parasites at any given time. In
addition, 20% of consultations, 16% of hospital admissions,
and 14% of hospital deaths are attributable to malaria.1,2
Papuan Indonesia (formerly Irian Jaya) and Papua New
Guinea have long been plagued by drug-resistant malaria.
Resistance to pyrimethamine and chloroquine in the Arso-
Waris-Upper Tor River areas of Papuan Indonesia is believed
to have arisen in 1959−1961 with the mass distribution of
medicated chloroquine and pyrimethamine salts.3 Resistance
of P. falciparum to chloroquine was reported from Kaliman-
tan in 1973 and from Papua in 1975.4,5 An increased risk of
chloroquine resistance was reported from the Jayapura region
of Papua, Indonesia in the1980s.6,7 Surveys conducted during
the 1990s showed high malaria prevalence rates (60−92%)
and levels of chloroquine treatment failure of up to 80%
among indigenous and immigrant communities of northern
and central Papuan Indonesia.8−12 However, due to its safety
profile, low cost, and relative success in treating mildly symp-
tomatic malaria infections among immune and semi-immune
patients, chloroquine remains the treatment of choice for ma-
laria, and no effective alternative strategy has been devel-
oped. Molecular markers of drug resistance in P. falciparum
could prove useful in defining the intensity of resistance in an
individual patient and the extent and severity of the problem
in communities.
The aim of this study was to examine P. falciparum chlo-
roquine resistance transporter (pfcrt) gene haplotypes in
parasite isolates with known in vivo or in vitro chloroquine
resistance responses.
MATERIALS AND METHODS
The Armopa region is located on the northwestern coast of
Indonesian Papua. Prior to Javanese transmigration in 1995,
there were small traditional villages and a single health clinic
in Armopa. No mass treatment or prophylaxis was practiced
before transmigrant arrivals, and the indigenous people of
Armopa did not use antimalarial drugs for prophylaxis. How-
ever, chloroquine, Fansidar (pyrimethamine and sulfadox-
ine) (F. Hoffmann La Roche, Basel, Switzerland), and qui-
nine were presumably available for treatment of clinical ma-
laria. Transmigrants, primarily from malaria-free Java and
Bali, had no previous exposure to malaria and no history of
antimalarial drug use before settling in Armopa. As per na-
tional health standards, they were given chloroquine for self
prophylaxis during their first three months after arrival;
thereafter, treatment with only chloroquine was provided for
uncomplicated cases of clinical malaria. Chloroquine is widely
used for treatment of clinical malaria among transmigrants
and is dispensed through a health clinic in each settlement.
Blood samples were collected in 1996−1999 from study vol-
unteers who were immigrants to the Armopa SP1 and SP2
sites and had no history of malaria or antimalarial drug use.
Patients who were positive for malaria were treated at the
health center with chloroquine, Fansidar, and quinine as the
respective first-, second-, and third-line drugs for uncompli-
cated malaria as per the Indonesian National Health Policy.
Chloroquine was given at a dose of 10 mg/kg on the first day,
followed by 5 mg/kg 12, 24, and 48 hours later. A single dose
of Fansidar (1 mg/kg of pyrimethamine and 20 mg/kg of
sulfadoxine) was given if there was chloroquine treatment
failure. This study was carried out after obtaining informed
consent from all adult participants and from parents or legal
guardians of minors, and was reviewed and approved by the
Ethics Committees for Protection of Human Subjects at the
Ministry of Health, Republic of Indonesia, the U.S. Navy
Medical Research Unit No. 2 (Jakarta, Indonesia), and The
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Copyright © 2003 by The American Society of Tropical Medicine and Hygiene
398
Walter and Eliza Hall Institute of Medical Research (Mel-
bourne, Australia) and the Papua New Guinea Medical Re-
search Advisory Committee.
RESULTS
Of 85 patients, 21 (24.7%) cases cleared their parasitemias
within 72 hours, had no recurrence during 28 days of follow-
up, and were classified as sensitive to chloroquine. Fifty pa-
tients had persistent or recurrent parasitemias and were clas-
sified as resistant to chloroquine. Data from 15 patient
samples were excluded from analysis due to incomplete clini-
cal histories, intercurrent infections with P. vivax, or an in-
ability to amplify gene products. Samples were analyzed for
mutations in the pfcrt gene after amplification by a polymer-
ase chain reaction (PCR) of DNA extracted from blood
samples, followed by restriction fragment length polymor-
phism (RFLP) analysis and DNA sequencing.13,14 The DNA
from a drug-sensitive strain (D10) was used as a positive con-
trol to monitor PCR conditions. As expected, the PCR prod-
uct was amplified with wild-type alleles of the pfcrt gene. No
PCR products were amplified in negative controls.
The results of pfcrt mutational analysis of samples from 50
cases of chloroquine treatment failure are shown in Table 1.
All 50 chloroquine-resistant samples carried the mutant pfcrt
76T allele. No mutation was detected at codon 73, but varia-
tions were found at codons 72, 74, and 75 in 50 samples:
SVMNT (24), CVIET (11), CVMNT (9), and SVIET (6).
Statistical analysis (chi-square test with Yates’ correction)
showed that the pfcrt mutation at codon 76 was strongly as-
sociated with chloroquine resistance (P < 0.0001).15 Among
the 21 chloroquine-sensitive samples, only one carried a mu-
tated pfcrt 76 allele.
Analysis of RFLP results from amplification of chloro-
quine-resistant P. falciparum laboratory strains K1, W2mef,
VNS, 7G8, a new isolate, 2300, from Timika on the southern
coast of Indonesian Papua, and two isolates, F2382 and
F1568, from Flores, Indonesia showed mutations in the pfcrt
gene (Table 2). Seven of these chloroquine-resistant labora-
tory strains showed three different pfcrt haplotypes with mu-
tations at codons 74, 75, and 76: CVMNT (7G8), CVIKT
(2300), and CVIET (K1, W2 mef, VNS, F2382, and F1568).
The wild-type haplotype CVMNK was found in the chloro-
quine-sensitive control strain D10.
The Wosera region of East Sepik province in Papua New
Guinea is highly endemic for malaria. Mutation analysis of
the genes involved in chloroquine resistance from Papua New
TABLE 1
In vitro chloroquine responses and Plasmodium falciparum chloro-
quine resistance transporter (pfcrt) gene haplotypes among malaria
patients in Armopa, Indonesian Papua*
Patient
Sampling
date
In vivo
response†
pfcrt codons
72 73 74 75 76
CQ004 12/6/96 RI S V M N T
CQ008 12/7/96 RI S V M N T
CQ010 3/10/97 RI S V M N T
CQ010 4/12/97 RIII S V M N T
CQ017 5/2/97 RIII S V M N T
CQ039 1/26/97 RI S V M N T
CQ039 4/24/97 RI S V M N T
CQ041 9/4/97 RIII S V M N T
CQ042 5/8/97 RIII S V M N T
CQ044 4/13/97 RIII S V M N T
CQ044 7/8/97 RIII S V M N T
CQ054 5/3/97 RIII S V M N T
CQ055 5/4/97 RIII S V M N T
CQ060 5/8/97 RIII S V M N T
CQ062 5/14/97 RIII S V M N T
CQ072 12/4/96 RI S V M N T
CQ091 4/16/97 RI S V M N T
CQ101 1/15/97 RIII S V M N T
CQ118 11/9/97 RII S V M N T
CQ041 8/10/97 RIII S V M N T
CQ041 10/30/97 RIII S V M N T
CQ072 4/21/97 RIII S V M N T
CQ080 5/5/97 RIII S V M N T
CQ080‡ 7/29/97 RI S V M N T
CQ076 10/15/96 RIII S V I E T
CQ104 5/2/97 RIII S V I E T
CQ106 11/6/96 RIII S V I E T
CQ020 3/11/97 RIII S V I E T
CQ116 5/3/97 RIII S V I E T
CQ026 3/15/97 RIII S V I E T
CQ078 8/29/97 RIII C V I E T
CQ078 11/26/97 RIII C V I E T
CQ077 2/28/97 RIII C V I E T
CQ082 11/8/97 RIII C V I E T
CQ094 3/23/97 RIII C V I E T
CQ113 10/12/97 RII C V I E T
CQ118 2/15/97 RIII C V I E T
CQ128 3/15/97 RIII C V I E T
CQ073 2/3/97 RIII C V I E T
CQ024 2/6/97 RIII C V I E T
CQ131 2/7/97 RII C V I E T
CQ003 1/21/97 RI C V M N T
CQ059 3/30/97 RI C V M N T
CQ067 4/30/97 RIII C V M N T
CQ022 4/4/97 RIII C V M N T
CQ022 4/23/97 RIII C V M N T
CQ087 8/1/97 RIII C V M N T
CQ095 12/13/96 RI C V M N T
CQ105 4/13/97 RI C V M N T
CQ036 4/26/97 RII C V M N T
CQ024 5/6/97 S C V M N K
CQ027 2/6/97 S C V M N K
CQ036 1/30/97 S C V M N K
CQ042 2/4/97 S C V M N K
CQ043 9/25/97 S C V M N T
CQ051 1/24/97 S C V M N K
CQ056 4/5/97 S C V M N K
CQ091 7/30/98 S C V M N K
CQ001 1/26/98 S C V M N K
CQ090 1/10/99 S C V M N K
CQ062 5/5/98 S C V M N K
CQ077 11/28/98 S C V M N K
CQ022 2/25/97 S C V M N K
CQ095 1/28/98 S C V M N K
CQ058 11/13/97 S C V M N K
CQ020 11/12/97 S C V M N K
CQ060 10/17/98 S C V M N K
TABLE 1 (Continued)
In vitro chloroquine responses and Plasmodium falciparum chloro-
quine resistance transporter (pfcrt) gene haplotypes among malaria
patients in Armopa, Indonesian Papua* (Continued)
Patient
Sampling
date
In vivo
response†
pfcrt codons
72 73 74 75 76
CQ098 1/28/98 S C V M N K
CQ0110 3/15/97 S C V M N K
CQ0102 2/3/97 S C V M N K
CQ113 7/12/98 S C V M N K
* Codon mutations are indicated in bold.
†R  resistant; S  sensitive.
‡ Sample from a patient with a recrudescent parasitemia that was not included in the
statistical analysis.
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Guinea has shown the presence of P. falciparum isolates car-
rying the pfcrt SVMNT haplotype, which is usually found in
South American parasites, but not the CVIET haplotype of
Southeast Asian isolates.16 The results of mutational analysis
of 21 samples of P. falciparum obtained from malaria patients
in Papua New Guinea are shown in Table 2. Fifteen of these
samples with chloroquine minimum inhibitory concentrations
(MICs) between 16 and 64 pmol had the 76T allele. However,
six isolates with MICs of 2−8 pmol had the wild-type pfcrt
allele at codons 72, 73, 74, 75, and 76. There were three pfcrt
haplotypes among the 21 Papua New Guinea samples (Table
2). The wild-type haplotype CVMNKwas observed in isolates
with MIC values of 2−8 pmol, while the chloroquine-resistant
pfcrt haplotypes CVMNT and SVMNT were observed in
samples with MICs between 16 and 64 pmol.
DISCUSSION
Although chloroquine resistance in P. falciparum has been
reported in Indonesia and Papua New Guinea since the early
1970s, molecular analysis and in vitro/in vivo responses to
antimalaria drugs have only recently been determined in this
region. This study analyzed the association of mutations in
TABLE 2
In vitro chloroquine responses and Plasmodium falciparum chloroquine resistance transporter (pfcrt) gene haplotypes among laboratory strains
and field samples*
Strains/samples Origin MIC50†
pfcrt codons
72 73 74 75 76
Laboratory strains
D10 Papua New Guinea 1 C V M N K
2300 Papua 75 C V I K T
K1 Thailand 130 C V I E T
W2 mef Southeast Asia 100 C V I E T
VNS Vietnam 80 C V I E T
F2382 Flores, Indonesia 30 C V I E T
F1568 Flores, Indonesia 128 C V I E T
7G8 South America 300 C V M N t
Field samples (from all Papua New Guinea)
DR1 64.0 S V M N T
DR3 64.0 S V M N T
DR9 32.0 S V M N T
DR21 32.0 S V M N T
DR24 32.0 S V M N T
DR5 16.0 S V M N T
DR12 16.0 S V M N T
DR15 16.0 S V M N T
DR22 16.0 S V M N T
DR2 32.0 S V M N T
DR11 64.0 C V M N T
DR4 32.0 C V M N T
DR18 64.0 C V M N T
DR20 16.0 C V M N T
DR23 16.0 C V M N T
DR14 2.0 C V M N K
DR17 2.0 C V M N K
DR19 8.0 C V M N K
DR10 2.0 C V M N K
DR13 2.0 C V M N K
DR16 2.0 C V M N K
* Codon mutations are indicated in bold.
† For the laboratory strains, 50% mean inhibitory concentration (MIC50) values are in nanomoles and were determined by an in vitro microtiter assay.
31 For the field isolates, values are in
picomoles and were calculated at the Australian Army Malaria Institute.
TABLE 3
Geographic distribution of Plasmodium falciparum chloroquine resistance transporter (pfcrt) gene haplotypes among chloroquine-resistant strains
of P. falciparum*
pfcrt codons
Chloroquine
susceptibility Location72 73 74 75 76
C V M N K Sensitive
C V M N T Resistant Papua, Papua New Guinea, South America
C V I K T Resistant Papua
C V I E T Resistant Papua, Southeast Asia, Africa
S V I E T Resistant Papua
S V M N T Resistant Papua, Papua New Guinea, South America
* Codon mutations are indicated in bold.
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the pfcrt gene in samples of P. falciparum that had been char-
acterized as chloroquine sensitive or resistant by in vitro or in
vivo tests.14 A strong association between mutations in the
pfcrt gene and chloroquine resistance (P < 0.0001) was ob-
served in those samples from individuals who had chloro-
quine treatment failure in vivo or had displayed chloroquine
MICs of 16−64 pmol in the in vitro test.
Studies to elucidate the molecular and biochemical mecha-
nism of resistance to chloroquine have been in progress for
more than a decade. Chloroquine resistance in P. falciparum
involves decreased accumulation of the drug. However, the
precise mechanism is not known.17 Mutations in the P. falci-
parum multidrug resistance 1 (pfmdr1) gene were implicated
and involvement of at least two genes was hypothesized; mu-
tations in both the pfcrt and the pfmdr1 genes appear to be
necessary for resistance to chloroquine.13,18,19 A mutation in
the pfcrt gene (located on chromosome 7) at codon 76, with a
change from lysine to threonine, has been invariably found in
chloroquine-resistant strains and also in chloroquine-resistant
field samples from Laos, Cameroon, Mozambique, Uganda,
and South America.13,20−27 Transformation of chloroquine-
sensitive isolates with the Dd2 pfcrt gene sequence containing
the 76T mutation consistently produced chloroquine-resistant
clones, and insertion of the wild-type pfcrt gene caused resis-
tant isolates to exhibit sensitivity to chloroquine.13 Studies on
field isolates have shown the occurrence of three haplotypes
of pfcrt gene alleles: CVMNK among chloroquine-sensitive
isolates, CVIET among chloroquine-resistant isolates from
Southeast Asia and Africa, and SVMNT among chloroquine-
resistant isolates from South America and Papua New
Guinea.13,16,28 The presence of the 76T pfcrt gene mutation
has been correlated with risk of therapeutic failure when ma-
laria due to P. falciparum is treated with chloroquine.22,29,30
Recently, an analysis of the genetic mutations associated with
chloroquine resistance in an area highly endemic for malaria
(the Wosera region of East Sepik province in Papua New
Guinea) was also reported.16 All (100%) samples from treat-
ment failures (Indonesian Papua) and 67% of the isolates
(Papua New Guinea) collected prior to treatment in the in
vitro studies carry the mutated pfcrt allele 76 (Tables 1 and 2).
In this study, analyses of known laboratory isolates that are
resistant to chloroquine showed the presence of a mutation in
the pfcrt gene. Samples collected in Papua New Guinea for in
vitro chloroquine susceptibility testing provide further sup-
port for our data from clinical studies in Armopa. Although a
mutated pfcrt codon 76 is invariably present in chloroquine-
resistant isolates, comparison of pfcrt haplotypes revealed
some interesting features. In both Armopa (Papua) and
Papua New Guinea, the CVMNK haplotype was the wild
type. In Papua New Guinea, the chloroquine-resistant haplo-
types detected were SVMNT and CVMNT, as demonstrated
in other studies (Table 3).16,28 Interestingly, the pfcrt haplo-
types CVIET (African, Southeast Asian) and SVMNT (South
American) were also detected in Papuan samples. In addition,
two new pfcrt haplotypes were detected in Papua that have
not been previously reported: SVIET, which was found in
clinical samples isolated from cases of treatment failure in
Armopa and CVIKT, a haplotype found in chloroquine-
resistant laboratory strain 2300, which was isolated in 1985 in
Timika, Papua. The presence of African, South American,
Southeast Asian, and two new chloroquine-resistant haplo-
types in these regions raises the question of the evolution of
these five haplotypes. They may have evolved by sequential
mutations of the gene in this region, where the parasite is
widely circulated, or the parasites with these haplotypes were
transferred into this region. This speculation on the origin of
haplotypes awaits detailed studies with data from other loci in
the genomes of P. falciparum isolates.
In conclusion, our results support the hypothesis that the
molecular basis of chloroquine resistance involves mutations
in the pfcrt gene and that detection of a mutated pfcrt allele 76
could predict potential chloroquine treatment failures.
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